COMPANY
Bexion Pharmaceuticals
Timeline
- Trial start Phase 1/Phase 2: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma source ↗
- Trial start Early phase 1: BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients source ↗
- Trial start Phase 1: A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) source ↗
- Trial start Phase 1: Continued Treatment for Participants Enrolled in Studies of BXQ-350 source ↗
- Trial start Phase 1: A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors source ↗
- Trial start 1: Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors source ↗
Upcoming milestones
- 2026-11 (ESTIMATED) · Phase 1/Phase 2 · BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma · NCT05322590
Clinical trials (lead sponsor) 6
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma | Phase 1/Phase 2 | Active, not recruiting | Jan 9, 2023 | 2026-11 (estimated) |
| NCT05291286 | BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients | Early phase 1 | Completed | Oct 17, 2022 | Dec 20, 2024 (actual) |
| NCT04404569 | Continued Treatment for Participants Enrolled in Studies of BXQ-350 | Phase 1 | Terminated | Jun 8, 2020 | Sep 23, 2024 (actual) |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) | Phase 1 | Terminated | May 24, 2021 | Oct 4, 2024 (actual) |
| NCT02859857 | Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors | 1 | Completed | Sep 1, 2016 | Jun 17, 2019 (actual) |
| NCT03967093 | A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors | Phase 1 | Terminated | Apr 15, 2019 | Jan 3, 2020 (actual) |
NIH awards 8
- NIH award 5R44CA136017-06 FY2015: $948,501 awarded for that fiscal year; activity R44 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS Nanovesicles for Treating Gliob source ↗
- NIH award 5R44CA136017-05 FY2014: $948,501 awarded for that fiscal year; activity R44 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS Nanovesicles for Treating Gliob source ↗
- NIH award 2R44CA136017-04 FY2013: $960,270 awarded for that fiscal year; activity R44 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS Nanovesicles for Treating Gliob source ↗
- NIH award 5R44CA136017-03 FY2011: $840,956 awarded for that fiscal year; activity R44 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS nanovesicles for Treating Gliob source ↗
- NIH award 2R44CA136017-02A1 FY2010: $670,367 awarded for that fiscal year; activity R44 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS nanovesicles for Treating Gli source ↗
- NIH award 1R43CA136017-01A1 FY2008: $273,138 awarded for that fiscal year; activity R43 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. SapC-DOPS Nanovesicles for Treating Gli source ↗
- NIH award 1R43CA117283-01A2 FY2008: $99,965 awarded for that fiscal year; activity R43 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., COVINGTON, KY. A Novel Biotherapeutic Treatment for Pan source ↗
- NIH award 1R43CA130228-01 FY2007: $145,306 awarded for that fiscal year; activity R43 (SBIR); PI XU, KEVIN; recipient as written: BEXION PHARMACEUTICALS, INC., Covington, KY. A novel biotherapeutic treatment for pros source ↗